Patents by Inventor Mikael Elofsson

Mikael Elofsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10011628
    Abstract: Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, such as epidemic keratoconjunctivitis, may be treated or prevented by administration of the tri- or tetravalent sialic acid derivatives.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: July 3, 2018
    Assignee: ADENOVIR PHARMA AB
    Inventors: Niklas Arnberg, Rémi Caraballo, Mikael Elofsson
  • Publication number: 20160207955
    Abstract: Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, such as epidemic keratoconjunctivitis, may be treated or prevented by administration of the tri- or tetravalent sialic acid derivatives.
    Type: Application
    Filed: August 28, 2014
    Publication date: July 21, 2016
    Applicant: Adenovir Pharma AB
    Inventors: Niklas Arnberg, Rémi Caraballo, Mikael Elofsson
  • Patent number: 8993622
    Abstract: The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 31, 2015
    Assignee: Eirium AB
    Inventors: Göran Wadell, Karin Edlund, Marten Strand, Emma Andersson, Christopher Öberg, Mikael Elofsson, Ya-Fang Mei
  • Publication number: 20130210915
    Abstract: The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.
    Type: Application
    Filed: June 13, 2011
    Publication date: August 15, 2013
    Inventors: Göran Wadell, Karin Edlund, Marten Strand, Emma Andersson, Christopher Öberg, Mikael Elofsson, Ya-Fang Mei
  • Publication number: 20100099674
    Abstract: A means for decreasing bacterial virulence in a mammal including man or in a plant by inhibition of the Type III secretion system at concentrations that do not prevent or substantially reduce bacterial growth comprises an N-substituted 7-quinolylmethyl amine, in particular one that is further substituted in 5- and 8-position on the quinoline ring. A corresponding therapeutic method and a pharmaceutical composition are also disclosed.
    Type: Application
    Filed: March 18, 2008
    Publication date: April 22, 2010
    Applicant: Innate Pharmaceuticals AB
    Inventor: Mikael Elofsson
  • Publication number: 20090099097
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.
    Type: Application
    Filed: November 7, 2008
    Publication date: April 16, 2009
    Applicant: Yale University
    Inventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Kyung Bo Kim
  • Patent number: 7476650
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: January 13, 2009
    Assignee: Yale University
    Inventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Kyung Bo Kim
  • Publication number: 20040266664
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.
    Type: Application
    Filed: June 17, 2004
    Publication date: December 30, 2004
    Applicant: Yale University
    Inventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Kyung Bo Kim
  • Patent number: 6831099
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: December 14, 2004
    Assignee: Yale University
    Inventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Ny Sin, Kyung Bo Kim